Cart
sales@molnova.com
AZ20
CAS No. 1233339-22-4
AZ20( AZ20 | AZ-20 | AZ 20 )
Catalog No. M10924 CAS No. 1233339-22-4
AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 51 | In Stock |
|
| 2MG | 31 | In Stock |
|
| 5MG | 49 | In Stock |
|
| 10MG | 75 | In Stock |
|
| 25MG | 138 | In Stock |
|
| 50MG | 243 | In Stock |
|
| 100MG | 360 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZ20
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.
-
DescriptionAZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.
-
In Vitro——
-
In Vivo——
-
SynonymsAZ20 | AZ-20 | AZ 20
-
PathwayCell Cycle/DNA Damage
-
TargetATM/ATR
-
RecptorATR| mTOR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1233339-22-4
-
Formula Weight412.51
-
Molecular FormulaC21H24N4O3S
-
Purity>98% (HPLC)
-
SolubilityEthanol: 3 mg/mL (7.27 mM); DMSO: 83 mg/mL (201.2 mM)
-
SMILESC[C@H]1N(C2=NC(C3=CC=CC4=C3C=CN4)=NC(C5(S(=O)(C)=O)CC5)=C2)CCOC1
-
Chemical Name(R)-4-(2-(1H-indol-4-yl)-6-(1-(methylsulfonyl)cyclopropyl)pyrimidin-4-yl)-3-methylmorpholine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
BAY-1895344
BAY-1895344 is a potent, selective, orally active ATR inhibitor with low-nanomolar potency; potently inhibits the proliferation of a broad spectrum of human tumor cell lines with mean IC50 of 78 nM; inhibits hydroxyurea-induced H2AX phosphorylation, exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models.Blood Cancer,Phase 1 Clinical
-
KU-60019
KU-60019 is an improved analogue of KU-55933, and is a potent, specific inhibitor of ATM kinase with IC50 of 6.3 nM, 270- and 1,600-fold selectivity over DNA-PKcs and ATR.
-
CP-466722
A poten and selective ATM inhibitor without effect on ATR kinase; does not inhibit PI3K, PI3K-like protein kinases or Abl kinase and disrupts ATM-dependent cell cycle checkpoints in cells.
